AVAC's Blog: P-Values

Charles Brown reflects on the important role of advocates in prevention research and what they need to succeed. This post was written for the WhatsUpHIV blog, which reported in real time on the 2014 HIV Research for Prevention conference in Cape Town, South Africa.

PrEP took centerstage at the morning plenaries at HIV R4P—and while the talks were going on, the French research agency announced that the IPERGAY trial of intermittent ("on demand") PrEP would be discontinuing randomization and placebo control after strong preliminary evidence of efficacy. This blog post gives a look at both developments.

Definate Nhamo and Teresia Njoki Otieno report on key conversations around women's HIV prevention. They discuss research findings on adherence in ARV-based prevention trials and the evolving body of evidence on hormonal contraceptive use and HIV risk. They also highlight the perspectives of young women who participated in the conference. This post was written for the WhatsUpHIV blog, which reported in real time on the 2014 HIV Research for Prevention conference in Cape Town, South Africa.

In this post (first appearing on Breakthroughs, a blog from GHTC), Emily Donaldson—program coordinator at AVAC—and Tom Harmon—senior policy analyst at the International AIDS Vaccine Initiative (IAVI)—write about the state of HIV prevention research funding as the first-ever conference devoted solely to HIV prevention research and development (R&D) takes place in Cape Town, South Africa, this week.